Phase 1 Results for a Novel Anti-VEGF/Anti-ANG2 Antibody

Pravin Dugel, MD

Show Description +

Pravin Dugel, MD, reviews the results of a phase 1 study evaluating RG7716, a novel anti-VEGF/anti-angiopoietin2 bispecific monoclonal antibody with potential to treat wet age-related macular degeneration and diabetic macular edema. Dr. Dugel reports on the results of the study and previews a pair of forthcoming phase 2 studies.

Posted: 8/03/2016

Keywords:

Anti-VEGF

Up Next

Name: Phase 1 Results for a Novel Anti-VEGF/Anti-ANG2 Antibody
Uploaded: 2016-08-03T12:38:00+00:00
Description: Pravin Dugel, MD, reviews the results of a phase 1 study evaluating RG7716, a novel anti-VEGF/anti-angiopoietin2 bispecific monoclonal antibody with potential to treat wet age-related macular degeneration and diabetic macular edema. Dr. Dugel reports on the results of the study and previews a pair of forthcoming phase 2 studies.